https://orcid.org/0000-0003-0468-8271
References
- Tio D, van Montfrans C, Ruijter CGH, et al. Effectiveness of 5% topical imiquimod for lentigo maligna treatment. Acta Derm Venereol. 2019;99(10):884–888.
- Papanikolaou M, Lawrence CM. Long-term outcomes of imiquimod-treated lentigo maligna. Clin Exp Dermatol. 2019;44(6):631–636.
- Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol. 2015;73(2):205–212.
- Pandit AS, Geiger EJ, Ariyan S, et al. Using topical imiquimod for the management of positive in situ margins after melanoma resection. Cancer Med. 2015;4(4):507–512.
- Chambers M, Swetter SM, Baker C, et al. Topical imiquimod for lentigo maligna: survival analysis of 103 cases with 17 years follow-up. J Drugs Dermatol. 2021;20(3):346–348.
- Swetter SM, Chen FW, Kim DD, et al. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type. J Am Acad Dermatol. 2015;72(6):1047–1053.
- Lallas A, Moscarella E, Kittler H, et al. Real-world experience on off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna. Br J Dermatol. 2021. DOI:10.1111/bjd.20407
- Moyer JS, Rudy S, Boonstra PS, et al. Efficacy of staged excision with permanent section margin control for cutaneous head and neck melanoma. JAMA Dermatol. 2017;153(3):282–288.
- Nosrati A, Berliner JG, Goel S, et al. Outcomes of melanoma in situ treated with mohs micrographic surgery compared with wide local excision. JAMA Dermatol. 2017;153(5):436–441.
- McLeod M, Choudhary S, Giannakakis G, et al. Surgical treatments for lentigo maligna: a review. Dermatol Surg. 2011;37(9):1210–1228.
- Hou JL, Reed KB, Knudson RM, et al. Five-year outcomes of wide excision and mohs micrographic surgery for primary lentigo maligna in an academic practice cohort. Dermatol Surg. 2015;41(2):211–218.
- Bittar PG, Bittar JM, Etzkorn JR, et al. Systematic review and Meta-analysis of local recurrence rates of head and neck cutaneous melanomas after wide local excision, mohs micrographic surgery, or staged excision. J Am Acad Dermatol. 2021.
- de Vries K, Greveling K, Prens LM, et al. Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. Br J Dermatol. 2016;174(3):588–593.
- Gautschi M, Oberholzer PA, Baumgartner M, et al. Prognostic markers in lentigo maligna patients treated with imiquimod cream: a long-term follow-up study. J Am Acad Dermatol. 2016;74(1):81–87.e1.
- Tio D, van der Woude J, Prinsen CAC, et al. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol. 2017;31(4):616–624.
- Marsden JR, Fox R, Boota NM, et al. Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study. Br J Dermatol. 2017;176(5):1148–1154.
- Hyde MA, Hadley ML, Tristani-Firouzi P, et al. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol. 2012;148(5):592–596.
- Joyce KM, Joyce CW, Jones DM, et al. An assessment of histological margins and recurrence of melanoma in situ. Plast Reconstr Surg Glob Open. 2015;3(2):e301.
- Moura FS, Homer LE, McKirdy SW. Histological peripheral margins and recurrence of melanoma in situ treated with wide local excision. J Skin Cancer. 2020;2020:8813050.